カテゴリ： Allied Market Research, 世界, 医療/バイオ

肺がんスクリーニングのグローバル市場（2021〜2031）：低線量コンピューター断層撮影（LDCT）、X線

■ 英語タイトル：Lung Cancer Screening Market By Type (Low-dose computed tomography (LDCT), X-ray), By Age group (50 and older, Below 50), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
	■ 発行会社/調査会社：Allied Market Research ■ 商品コード：ALD23FB161 ■ 発行日：2022年10月 ■ 調査対象地域：グローバル ■ 産業分野：医療 ■ ページ数：271 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

■ 販売価格オプション（消費税別）

Online Only（1名閲覧、印刷不可）	USD3,570 ⇒換算￥542,640	見積依頼/購入/質問フォーム
Single User（1名閲覧）	USD5,730 ⇒換算￥870,960	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）	USD9,600 ⇒換算￥1,459,200	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[肺がんスクリーニングのグローバル市場（2021〜2031）：低線量コンピューター断層撮影（LDCT）、X線]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に879.59百万ドルであった世界の肺がんスクリーニング市場規模が、2031年までに1,853.04百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）7.7%で成長すると予測しています。本レポートは、肺がんスクリーニングの世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、種類別（低線量コンピューター断層撮影（LDCT）、X線）分析、年齢層別（50歳以上、50歳以下）分析、エンドユーザー別（病院、診断センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Canon Medical Systems Corporation、Eon Health、FUJIFILM Holdings Corporation、General Electric incorporated (GE Healthcare)、Koninklijke Philips N.V.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の肺がんスクリーニング市場規模：種類別
- 低線量コンピューター断層撮影（LDCT）における市場規模
- X線における市場規模
・世界の肺がんスクリーニング市場規模：年齢層別
- 50歳以上における市場規模
- 50歳以下における市場規模
・世界の肺がんスクリーニング市場規模：エンドユーザー別
- 病院における市場規模
- 診断センターにおける市場規模
- その他における市場規模
・世界の肺がんスクリーニング市場規模：地域別
- 北米の肺がんスクリーニング市場規模
- ヨーロッパの肺がんスクリーニング市場規模
- アジア太平洋の肺がんスクリーニング市場規模
- 中南米・中東・アフリカの肺がんスクリーニング市場規模
・企業状況
・企業情報

世界の肺がんスクリーニング市場は、2021年には8億7,959万ドルと評価され、2022年から2031年まで年平均成長率7.7%で成長して2031年には18億5,304万ドルに達すると予測されています。

肺がんスクリーニングとは、治癒の可能性が高い時点で、症状が出る前に初期の肺がんを発見する方法を指します。肺がんは、肺から始まるがんの中で最も一般的なものです。肺がんの主な原因はタバコです。腫瘍細胞は顕微鏡の外観から、小細胞肺がん（SCLC）と非小細胞肺がん（NSCLC）に分類されます。肺がんのスクリーニング検査として推奨されているのは、低線量コンピューター断層撮影とX線検査です。

世界の肺がんスクリーニング市場の成長は、世界全体の肺がん有病率の憂慮すべき増加、喫煙人口の増加、検診方法の技術革新が主な要因です。例えば、2020年の米国臨床腫瘍学会（ASCO）は、肺がんは女性と男性で2番目に多いがんの種類であると述べています。また、肺がんの早期発見に対する政府の取り組みが活発化していることも、市場の成長を後押ししています。

さらに、肺がんの早期スクリーニングに関する意識の高まりと肺がんの罹患率の急増は、効果的なスクリーニング検査に対する需要を増加させる原因となっています。これらの要因は、予測期間中に肺がんスクリーニング市場に成長機会をもたらすと期待されています。
しかし、発展途上国におけるスクリーニング検査費用の高騰やスクリーニング技術に関する認識不足は、市場の成長を妨げる要因になると予想されます。

肺がんスクリーニング市場は、種類、年齢層、エンドユーザー、地域に区分されます。種類別では、市場は低線量コンピュータ断層撮影（LDCT）とX線に分類されます。年齢層別では、市場は50歳以上と50歳未満に分別されます。エンドユーザー別では、病院、診断センター、その他に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）に市場を分けて分析しています。

世界の肺がんスクリーニング市場で事業を展開する主な主要企業は、Canon Medical Systems U.S. Inc.、Eon Health、富士フィルムホールディングス株式会社、General Electric Company (GE Healthcare)、Koninklijke Philips N.V.、Medtronic Plc、Microsoft Corporation (Nuance Communications, Inc.)、Penrad Technologies Inc.、Siemens Ag、Volpara Solutions Limitedです。

〈ステークホルダーにとっての主なメリット〉
・2021年から2031年までの肺がんスクリーニング市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、肺がんスクリーニングの市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・肺がんスクリーニング市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・肺がんスクリーニングの地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
種類別
低線量コンピュータ断層撮影（LDCT）
X線検査

年齢層別
50歳以上
50歳未満

エンドユーザー別
病院
診断センター
その他

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
キヤノンメディカルシステムズ株式会社
Eon Health
富士フイルムホールディングス株式会社
General Electric incorporated (GE Healthcare)
Koninklijke Philips N.V.
Medtronic plc
Nuance Communications, Inc.
Penrad Technologies Inc
Siemens AG (Siemens Healthineers AG)
Volpara Solutions Limited

*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: LUNG CANCER SCREENING MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Low-dose computed tomography (LDCT)
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 X-ray
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: LUNG CANCER SCREENING MARKET, BY AGE GROUP
5.1 Overview
5.1.1 Market size and forecast
5.2 50 and older
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Below 50
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: LUNG CANCER SCREENING MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Hospitals Lung Cancer Screening Market by Type
6.2.4.1 Public Market size and forecast, by region
6.2.4.2 Private Market size and forecast, by region
6.3 Diagnostic Centers
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: LUNG CANCER SCREENING MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Age group
7.2.4 North America Market size and forecast, by End User
7.2.4.1 North America Hospitals Lung Cancer Screening Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Age group
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Age group
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Age group
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Age group
7.3.4 Europe Market size and forecast, by End User
7.3.4.1 Europe Hospitals Lung Cancer Screening Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Age group
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Age group
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Age group
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Age group
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Age group
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Age group
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Age group
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.4.1 Asia-Pacific Hospitals Lung Cancer Screening Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Age group
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Age group
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Age group
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Age group
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Age group
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Age group
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Age group
7.5.4 LAMEA Market size and forecast, by End User
7.5.4.1 LAMEA Hospitals Lung Cancer Screening Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Age group
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Age group
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Age group
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Age group
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Canon Medical Systems Corporation
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Eon Health
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 FUJIFILM Holdings Corporation
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 General Electric incorporated (GE Healthcare)
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Koninklijke Philips N.V.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Medtronic plc
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Nuance Communications, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Penrad Technologies Inc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Siemens AG (Siemens Healthineers AG)
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Volpara Solutions Limited
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. LUNG CANCER SCREENING MARKET, FOR LOW-DOSE COMPUTED TOMOGRAPHY (LDCT), BY REGION, 2021-2031 ($MILLION)
TABLE 3. LUNG CANCER SCREENING MARKET FOR LOW-DOSE COMPUTED TOMOGRAPHY (LDCT), BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. LUNG CANCER SCREENING MARKET, FOR X-RAY, BY REGION, 2021-2031 ($MILLION)
TABLE 5. LUNG CANCER SCREENING MARKET FOR X-RAY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 7. LUNG CANCER SCREENING MARKET, FOR 50 AND OLDER, BY REGION, 2021-2031 ($MILLION)
TABLE 8. LUNG CANCER SCREENING MARKET FOR 50 AND OLDER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. LUNG CANCER SCREENING MARKET, FOR BELOW 50, BY REGION, 2021-2031 ($MILLION)
TABLE 10. LUNG CANCER SCREENING MARKET FOR BELOW 50, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. GLOBAL LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 12. LUNG CANCER SCREENING MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. LUNG CANCER SCREENING MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 15. LUNG CANCER SCREENING MARKET, FOR PUBLIC, BY REGION, 2021-2031 ($MILLION)
TABLE 16. LUNG CANCER SCREENING MARKET, FOR PRIVATE, BY REGION, 2021-2031 ($MILLION)
TABLE 17. LUNG CANCER SCREENING MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 ($MILLION)
TABLE 18. LUNG CANCER SCREENING MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. LUNG CANCER SCREENING MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. LUNG CANCER SCREENING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. LUNG CANCER SCREENING MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 22. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 23. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. U.S. LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 28. U.S. LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 29. U.S. LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 30. CANADA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 31. CANADA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 32. CANADA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 33. MEXICO LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. MEXICO LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 35. MEXICO LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 36. EUROPE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 37. EUROPE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 38. EUROPE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 39. EUROPE HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 40. EUROPE LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 41. GERMANY LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 42. GERMANY LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 43. GERMANY LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 44. FRANCE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 45. FRANCE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 46. FRANCE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. UK LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. UK LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 49. UK LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 50. ITALY LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 51. ITALY LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 52. ITALY LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 53. SPAIN LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. SPAIN LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 55. SPAIN LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 58. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 59. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 61. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 62. ASIA-PACIFIC HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 64. JAPAN LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 65. JAPAN LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 66. JAPAN LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 67. CHINA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 68. CHINA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 69. CHINA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 70. AUSTRALIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. AUSTRALIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 72. AUSTRALIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 73. INDIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 74. INDIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 75. INDIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 76. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 77. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 78. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 80. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 82. LAMEA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 83. LAMEA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 84. LAMEA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 85. LAMEA HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 86. LAMEA LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 87. BRAZIL LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 88. BRAZIL LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 89. BRAZIL LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 90. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 91. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 92. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 93. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 95. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 96. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 97. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 98. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 99.CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT
TABLE 100.CANON MEDICAL SYSTEMS CORPORATION: OPERATING SEGMENTS
TABLE 101.CANON MEDICAL SYSTEMS CORPORATION: PRODUCT PORTFOLIO
TABLE 102.CANON MEDICAL SYSTEMS CORPORATION: NET SALES,
TABLE 103.CANON MEDICAL SYSTEMS CORPORATION: KEY STRATERGIES
TABLE 104.EON HEALTH: COMPANY SNAPSHOT
TABLE 105.EON HEALTH: OPERATING SEGMENTS
TABLE 106.EON HEALTH: PRODUCT PORTFOLIO
TABLE 107.EON HEALTH: NET SALES,
TABLE 108.EON HEALTH: KEY STRATERGIES
TABLE 109.FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT
TABLE 110.FUJIFILM HOLDINGS CORPORATION: OPERATING SEGMENTS
TABLE 111.FUJIFILM HOLDINGS CORPORATION: PRODUCT PORTFOLIO
TABLE 112.FUJIFILM HOLDINGS CORPORATION: NET SALES,
TABLE 113.FUJIFILM HOLDINGS CORPORATION: KEY STRATERGIES
TABLE 114.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): COMPANY SNAPSHOT
TABLE 115.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): OPERATING SEGMENTS
TABLE 116.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): PRODUCT PORTFOLIO
TABLE 117.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): NET SALES,
TABLE 118.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): KEY STRATERGIES
TABLE 119.KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
TABLE 120.KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
TABLE 121.KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
TABLE 122.KONINKLIJKE PHILIPS N.V.: NET SALES,
TABLE 123.KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES
TABLE 124.MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 125.MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 126.MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 127.MEDTRONIC PLC: NET SALES,
TABLE 128.MEDTRONIC PLC: KEY STRATERGIES
TABLE 129.NUANCE COMMUNICATIONS, INC.: COMPANY SNAPSHOT
TABLE 130.NUANCE COMMUNICATIONS, INC.: OPERATING SEGMENTS
TABLE 131.NUANCE COMMUNICATIONS, INC.: PRODUCT PORTFOLIO
TABLE 132.NUANCE COMMUNICATIONS, INC.: NET SALES,
TABLE 133.NUANCE COMMUNICATIONS, INC.: KEY STRATERGIES
TABLE 134.PENRAD TECHNOLOGIES INC: COMPANY SNAPSHOT
TABLE 135.PENRAD TECHNOLOGIES INC: OPERATING SEGMENTS
TABLE 136.PENRAD TECHNOLOGIES INC: PRODUCT PORTFOLIO
TABLE 137.PENRAD TECHNOLOGIES INC: NET SALES,
TABLE 138.PENRAD TECHNOLOGIES INC: KEY STRATERGIES
TABLE 139.SIEMENS AG (SIEMENS HEALTHINEERS AG): COMPANY SNAPSHOT
TABLE 140.SIEMENS AG (SIEMENS HEALTHINEERS AG): OPERATING SEGMENTS
TABLE 141.SIEMENS AG (SIEMENS HEALTHINEERS AG): PRODUCT PORTFOLIO
TABLE 142.SIEMENS AG (SIEMENS HEALTHINEERS AG): NET SALES,
TABLE 143.SIEMENS AG (SIEMENS HEALTHINEERS AG): KEY STRATERGIES
TABLE 144.VOLPARA SOLUTIONS LIMITED: COMPANY SNAPSHOT
TABLE 145.VOLPARA SOLUTIONS LIMITED: OPERATING SEGMENTS
TABLE 146.VOLPARA SOLUTIONS LIMITED: PRODUCT PORTFOLIO
TABLE 147.VOLPARA SOLUTIONS LIMITED: NET SALES,
TABLE 148.VOLPARA SOLUTIONS LIMITED: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

肺がんスクリーニングのグローバル市場（2021〜2031）：低線量コンピューター断層撮影（LDCT）、X線

グローバル市場調査会社